4 Citations (Scopus)

Abstract

Prophylactic and therapeutic immunization strategies are an effective method to control human papillomavirus (HPV)-associated diseases and cancers. Current protective virus-like particle and capsid-based vaccines are highly protective against vaccine-matched HPV types, and continued improvements in second-generation vaccines will lead to broader protection and cross-protection against the cancer-associated types. Increasing the effectiveness of broadly cross-protective L2-based immunogens will require adjuvants that activate innate immunity to thus enhance adaptive immunity. Therapeutic immunization strategies are needed to control and cure clinical disease and HPV-associated cancers. Significant advances in strategies to improve induction of cell-mediated immunity to HPV early (and capsid) proteins have been pretested in preclinical animal papillomavirus models. Several of these effective protocols have translated into successful therapeutic immune-mediated clearance of clinical lesions. Nevertheless, there are significant challenges in activating immunity to cancer-associated lesions due to various immune downregulatory events that are triggered by persistent HPV infections. A better understanding of immune responses to HPV lesions in situ is needed to optimize immune effector T cells that efficiently locate to sites of infection and which should lead to an effective immunotherapeutic management of this important human viral pathogen. The most effective immunization strategy may well require combination antiviral and immunotherapeutic treatments to achieve complete clearance of HPV infections and associated cancers.

Original languageEnglish (US)
Pages (from-to)252-264
Number of pages13
JournalCurrent Problems in Dermatology (Switzerland)
Volume45
DOIs
StatePublished - Jan 1 2014

Fingerprint

Immunization
Vaccines
Papillomavirus Infections
Neoplasms
Cross Protection
Papillomavirus Vaccines
Capsid
Capsid Proteins
Adaptive Immunity
Therapeutics
Innate Immunity
Cellular Immunity
Virion
Antiviral Agents
Immunity
Animal Models
T-Lymphocytes
Infection

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

@article{333323d0f2b748bfbd13f9ebc0f916d0,
title = "Vaccines and immunization against human papillomavirus",
abstract = "Prophylactic and therapeutic immunization strategies are an effective method to control human papillomavirus (HPV)-associated diseases and cancers. Current protective virus-like particle and capsid-based vaccines are highly protective against vaccine-matched HPV types, and continued improvements in second-generation vaccines will lead to broader protection and cross-protection against the cancer-associated types. Increasing the effectiveness of broadly cross-protective L2-based immunogens will require adjuvants that activate innate immunity to thus enhance adaptive immunity. Therapeutic immunization strategies are needed to control and cure clinical disease and HPV-associated cancers. Significant advances in strategies to improve induction of cell-mediated immunity to HPV early (and capsid) proteins have been pretested in preclinical animal papillomavirus models. Several of these effective protocols have translated into successful therapeutic immune-mediated clearance of clinical lesions. Nevertheless, there are significant challenges in activating immunity to cancer-associated lesions due to various immune downregulatory events that are triggered by persistent HPV infections. A better understanding of immune responses to HPV lesions in situ is needed to optimize immune effector T cells that efficiently locate to sites of infection and which should lead to an effective immunotherapeutic management of this important human viral pathogen. The most effective immunization strategy may well require combination antiviral and immunotherapeutic treatments to achieve complete clearance of HPV infections and associated cancers.",
author = "Neil Christensen and Budgeon, {Lynn R.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1159/000356183",
language = "English (US)",
volume = "45",
pages = "252--264",
journal = "Current Problems in Dermatology",
issn = "1421-5721",
publisher = "S. Karger AG",

}

Vaccines and immunization against human papillomavirus. / Christensen, Neil; Budgeon, Lynn R.

In: Current Problems in Dermatology (Switzerland), Vol. 45, 01.01.2014, p. 252-264.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Vaccines and immunization against human papillomavirus

AU - Christensen, Neil

AU - Budgeon, Lynn R.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Prophylactic and therapeutic immunization strategies are an effective method to control human papillomavirus (HPV)-associated diseases and cancers. Current protective virus-like particle and capsid-based vaccines are highly protective against vaccine-matched HPV types, and continued improvements in second-generation vaccines will lead to broader protection and cross-protection against the cancer-associated types. Increasing the effectiveness of broadly cross-protective L2-based immunogens will require adjuvants that activate innate immunity to thus enhance adaptive immunity. Therapeutic immunization strategies are needed to control and cure clinical disease and HPV-associated cancers. Significant advances in strategies to improve induction of cell-mediated immunity to HPV early (and capsid) proteins have been pretested in preclinical animal papillomavirus models. Several of these effective protocols have translated into successful therapeutic immune-mediated clearance of clinical lesions. Nevertheless, there are significant challenges in activating immunity to cancer-associated lesions due to various immune downregulatory events that are triggered by persistent HPV infections. A better understanding of immune responses to HPV lesions in situ is needed to optimize immune effector T cells that efficiently locate to sites of infection and which should lead to an effective immunotherapeutic management of this important human viral pathogen. The most effective immunization strategy may well require combination antiviral and immunotherapeutic treatments to achieve complete clearance of HPV infections and associated cancers.

AB - Prophylactic and therapeutic immunization strategies are an effective method to control human papillomavirus (HPV)-associated diseases and cancers. Current protective virus-like particle and capsid-based vaccines are highly protective against vaccine-matched HPV types, and continued improvements in second-generation vaccines will lead to broader protection and cross-protection against the cancer-associated types. Increasing the effectiveness of broadly cross-protective L2-based immunogens will require adjuvants that activate innate immunity to thus enhance adaptive immunity. Therapeutic immunization strategies are needed to control and cure clinical disease and HPV-associated cancers. Significant advances in strategies to improve induction of cell-mediated immunity to HPV early (and capsid) proteins have been pretested in preclinical animal papillomavirus models. Several of these effective protocols have translated into successful therapeutic immune-mediated clearance of clinical lesions. Nevertheless, there are significant challenges in activating immunity to cancer-associated lesions due to various immune downregulatory events that are triggered by persistent HPV infections. A better understanding of immune responses to HPV lesions in situ is needed to optimize immune effector T cells that efficiently locate to sites of infection and which should lead to an effective immunotherapeutic management of this important human viral pathogen. The most effective immunization strategy may well require combination antiviral and immunotherapeutic treatments to achieve complete clearance of HPV infections and associated cancers.

UR - http://www.scopus.com/inward/record.url?scp=84922480227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922480227&partnerID=8YFLogxK

U2 - 10.1159/000356183

DO - 10.1159/000356183

M3 - Article

C2 - 24643192

AN - SCOPUS:84922480227

VL - 45

SP - 252

EP - 264

JO - Current Problems in Dermatology

JF - Current Problems in Dermatology

SN - 1421-5721

ER -